| 1 |
34936813 | Mammalian Target of Rapamycin Inhibitor Rapamycin Alleviates 7-Ketocholesterol Induced Inflammatory Responses and Vascular Endothelial Growth Factor Elevation by Regulating MAPK Pathway in Human Retinal Pigment Epithelium Cells. | 2022 Mar |
2 |
| 2 |
35300418 | Rapamycin and Resveratrol Modulate the Gliotic and Pro-Angiogenic Response in Müller Glial Cells Under Hypoxia. | 2022 |
2 |
| 3 |
33479328 | Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin. | 2021 Jan 21 |
1 |
| 4 |
31990892 | The Use of Sirolimus for Treatment of Orbital Lymphatic Malformations: A Systematic Review. | 2020 May/Jun |
1 |
| 5 |
32692750 | Retraction: Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF. | 2020 |
1 |
| 6 |
32885169 | Hierarchical Capillary Coating to Biofunctionlize Drug-Eluting Stent for Improving Endothelium Regeneration. | 2020 |
3 |
| 7 |
33114161 | Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis. | 2020 Oct 23 |
1 |
| 8 |
30846465 | Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. | 2019 Apr |
2 |
| 9 |
31354297 | Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression. | 2019 |
2 |
| 10 |
31408438 | Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. | 2019 Aug 13 |
1 |
| 11 |
29670840 | Investigating Effect of Rapamycin and Metformin on Angiogenesis in Hepatocellular Carcinoma Cell Line. | 2018 Mar |
2 |
| 12 |
30186415 | Effect of silencing lncRNATUG1 on rapamycin-induced inhibition of endothelial cell proliferation and migration. | 2018 Sep |
2 |
| 13 |
28963126 | EGF regulation of proximal tubule cell proliferation and VEGF-A secretion. | 2017 Sep |
1 |
| 14 |
26427711 | Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression. | 2016 Jan |
2 |
| 15 |
27103123 | Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. | 2016 Jun |
2 |
| 16 |
24882386 | Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation. | 2015 Jan |
2 |
| 17 |
25988388 | Suppression of the proliferation of hypoxia-Induced retinal pigment epithelial cell by rapamycin through the /mTOR/HIF-1α/VEGF/ signaling. | 2015 Jun |
1 |
| 18 |
26382207 | Retraction: 'Rapamycin Attenuates Liver Graft Injury in Cirrhotic Recipient-The Significance of Down-Regulation of Rho-ROCK-VEGF Pathway' by K. Man, M. Su, K.T. Ng, C.M. Lo, Y. Zhao, J.W. Ho, C.K. Sun, T.K. Lee, and S.T. Fan. | 2015 Oct |
1 |
| 19 |
24018642 | Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. | 2014 Jan 1 |
1 |
| 20 |
24451985 | Stimulatory Effect of Vascular Endothelial Growth Factor on Proliferation and Migration of Porcine Trophectoderm Cells and Their Regulation by the Phosphatidylinositol-3-Kinase-AKT and Mitogen-Activated Protein Kinase Cell Signaling Pathways. | 2014 Mar |
1 |
| 21 |
23403511 | Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under normoxia. | 2013 Apr |
1 |
| 22 |
20207175 | Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin. | 2012 Jan-Feb |
1 |
| 23 |
21617191 | Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. | 2012 Jan |
1 |
| 24 |
22117756 | Rapamycin inhibits transforming growth factor β-induced peritoneal angiogenesis by blocking the secondary hypoxic response. | 2012 Aug |
1 |
| 25 |
22419707 | Proangiogenic effect of TSH in human microvascular endothelial cells through its membrane receptor. | 2012 May |
1 |
| 26 |
22900063 | Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. | 2012 |
2 |
| 27 |
23209838 | Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway. | 2012 |
1 |
| 28 |
21252047 | Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. | 2011 Aug |
1 |
| 29 |
21363918 | Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. | 2011 Mar 1 |
1 |
| 30 |
21380626 | Growth of kidney-transplanted pediatric patients treated with sirolimus. | 2011 Jun |
2 |
| 31 |
21964931 | Ginsenoside-Rg1 mediates a hypoxia-independent upregulation of hypoxia-inducible factor-1α to promote angiogenesis. | 2011 Dec |
1 |
| 32 |
22027770 | [Effect of vascular endothelial growth factor on bone marrow-derived mesenchymal stem cell proliferation and the signaling mechanism]. | 2011 Oct |
1 |
| 33 |
19634141 | Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. | 2010 Jan 15 |
1 |
| 34 |
19919613 | Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient. | 2010 Jan-Feb |
2 |
| 35 |
20070623 | Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity. | 2010 Aug |
1 |
| 36 |
20106729 | Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. | 2010 Apr |
1 |
| 37 |
20179227 | Everolimus. | 2010 Mar 1 |
1 |
| 38 |
20555322 | Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. | 2010 Sep |
1 |
| 39 |
20922700 | [Skin cancer in renal transplant recipients]. | 2010 Sep-Oct |
2 |
| 40 |
21189444 | The influence of immunosuppressive drugs on vascular endothelial growth factor production in relation to VEGF -1154 g and -2578 C genotypes. | 2010 Dec |
3 |
| 41 |
18927120 | Sirolimus interacts with pathways essential for podocyte integrity. | 2009 Feb |
2 |
| 42 |
19002496 | Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. | 2009 May |
3 |
| 43 |
19081609 | Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. | 2009 Mar |
1 |
| 44 |
19260835 | ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin. | 2009 Mar |
1 |
| 45 |
19336014 | Optimizing recent advances in metastatic renal cell carcinoma. | 2009 May |
1 |
| 46 |
19347904 | Rapamycin selectively reduces the association of transcripts containing complex 5' UTRs with ribosomes in C4-2B prostate cancer cells. | 2009 Jun 1 |
1 |
| 47 |
19789339 | The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. | 2009 Oct 1 |
2 |
| 48 |
19797172 | Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation. | 2009 Nov 6 |
1 |
| 49 |
18278068 | N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. | 2008 Jun 26 |
1 |
| 50 |
18305085 | Vascular endothelial growth factor protein levels and gene expression in peripheral monocytes after stenting: a randomized comparative study of sirolimus: eluting and bare metal stents. | 2008 Mar |
2 |